3 results
During the course of the study 2 randomisation questions will be adressed. Both questions concern patients in the high risk group.Randomisation question 1: Will the addition of Doxorubicin to the first 4 standard IVA chemotherapy courses lead to a…
The primary objective is to evaluate the feasibility and adherence of 6 weeks of rehabilitation with the SEA in participants who underwent TL. The secondary objective is to examine if the SEA is an effective tool to improve swallowing function and…
The goal of the fenebrutinib development program in MS is to evaluate the benefits and risks of fenebrutinib treatment across the spectrum of patients with MS. Based on the existing toxicology, pharmacology, and clinical experience with fenebrutinib…